Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Takeda (Details)

v3.24.1.u1
Licensing and Other Arrangements - Takeda (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 209 Months Ended
Nov. 01, 2006
Feb. 28, 2009
Mar. 31, 2024
Mar. 31, 2024
Dec. 31, 2023
Licensing and other arrangements          
Revenue from contracts with customers     $ 1,000    
Takeda Pharmaceutical Company Limited | Collaboration Agreement          
Licensing and other arrangements          
Maximum milestone payments entitled to receive     16,000 $ 16,000  
Revenue from contracts with customers       3,000  
Contract assets     0 0 $ 0
Contract liabilities     0 0 0
Capitalized contract costs     $ 0 $ 0 $ 0
Takeda Pharmaceutical Company Limited | Collaboration Agreement | TAK-079 and TAK-169          
Licensing and other arrangements          
Maximum milestone payments entitled to receive $ 19,000        
Minimum period eligible to receive royalties 13 years 6 months        
Royalty payment period from the first commercial sale of each royalty-bearing discovery product 12 years        
Takeda Pharmaceutical Company Limited | Collaboration Agreement | Other antibodies          
Licensing and other arrangements          
Maximum eligible milestone payments receivable per discovery product candidate   $ 3,300      
Minimum period eligible to receive royalties   10 years